Want to see AVTX full AI Analyst Report?
AVTX Stock Chart & Stats
$14.43
-$0.55(-7.32%)
At close: 4:00 PM EST
$14.43
-$0.55(-7.32%)
Day’s Range― - ―
52-Week Range$4.61 - $24.27
Previous CloseN/A
Volume10.82K
Average Volume (3M)1.87M
Market Cap
$1.01B
Enterprise Value$151.27M
Total Cash (Recent Filing)$81.99M
Total Debt (Recent Filing)$2.33M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Jul 30, 2026EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.83
Shares Outstanding52,565,570
10 Day Avg. Volume2,226,539
30 Day Avg. Volume1,865,941
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.93
Price to Sales (P/S)4125.96
P/FCF Ratio-4.73
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue2.56K
Enterprise Value/Gross Profit-7.34
Enterprise Value/Ebitda-1.79
Forecast
1Y Price Target
$44.90Price Target Upside211.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical-stage Efficacy (Phase 2 HS)Robust Phase 2 LOTUS efficacy and favorable safety create a durable foundation for a registrational Phase 3 program. If replicated, the data meaningfully de-risks late-stage development, strengthens regulatory arguments and supports physician adoption and commercial positioning in HS over the next 2-6 months and beyond.
Pipeline Expansion (AVTX-010)Adding AVTX-010 deepens Avalo's IL-1β franchise, creating multiple clinical assets addressing inflammatory diseases. A follow-on candidate with less frequent dosing provides strategic differentiation, enhances IP breadth and spreads program risk, improving long-term development optionality and franchise value.
Low Financial LeverageZero TTM debt materially reduces near-term default and covenant risk, preserving strategic flexibility. For a cash-burning development-stage biotech, low leverage lowers fixed obligations and helps prioritize R&D spending or M&A, improving solvency resilience across financing cycles.
Bears Say
Sustained Cash BurnPersistent negative operating and free cash flow near -$60M TTM signals heavy ongoing funding needs. This constrains the company's ability to self-fund multiple late-stage programs, increases execution risk if costs rise, and makes strategic timing of trials and milestones dependent on external financing.
Minimal Revenue & Persistent LossesThe collapse of revenue and sustained operating losses means Avalo lacks recurring commercial cash flow to offset development spend. Negative returns on equity and ongoing losses reduce internal funding capacity, making long-term program advancement contingent on trial success or continued capital markets access.
Financing And Dilution RiskLarge equity and warrant offerings materially alter the cap table and indicate reliance on external capital to fund development. While proceeds extend runway, repeated equity raises can dilute holders, complicate incentives and signal funding dependence—structural risks for execution and shareholder alignment.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics, Inc.’s price range in the past 12 months?
Avalo Therapeutics, Inc. lowest stock price was $4.61 and its highest was $24.27 in the past 12 months.
What is Avalo Therapeutics, Inc.’s market cap?
Avalo Therapeutics, Inc.’s market cap is $1.01B.
When is Avalo Therapeutics, Inc.’s upcoming earnings report date?
Avalo Therapeutics, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 20 days.
How were Avalo Therapeutics, Inc.’s earnings last quarter?
Avalo Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.025 by $0.045.
Is Avalo Therapeutics, Inc. overvalued?
According to Wall Street analysts Avalo Therapeutics, Inc.’s price is currently Undervalued.
Does Avalo Therapeutics, Inc. pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
What is Avalo Therapeutics, Inc.’s EPS estimate?
Avalo Therapeutics, Inc.’s EPS estimate is -0.58.
How many shares outstanding does Avalo Therapeutics, Inc. have?
Avalo Therapeutics, Inc. has 52,565,570 shares outstanding.
What happened to Avalo Therapeutics, Inc.’s price movement after its last earnings report?
Avalo Therapeutics, Inc. reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.025. Following the earnings report the stock price went down -0.451%.
Which hedge fund is a major shareholder of Avalo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AVTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avalo Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.90 (211.16% Upside)
$44.90 (211.16% Upside)
Blogger Sentiment
Bullish
AVTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 894.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 24.0%
Last 30 Days ▲ 24.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
296.08%
12-Months-Change
Fundamentals
Return on Equity
-97.55%
Trailing 12-Months
Asset Growth
-27.89%
Trailing 12-Months
Company Description
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
AVTX Stock 12 Month Forecast
Average Price Target
$44.90
▲(211.16% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Forte Biosciences
―
Milestone Pharmaceuticals
―
Elicio Therapeutics
―
Fractyl Health, Inc.
―
Ownership Overview
0.72% Insiders
8.75% Mutual Funds
40.95% Other Institutional Investors
38.26% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---